Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Table 3 Univariable and multivariable analysis for progression-free survival (PFS)

Variables	Univariable analysis		Multivariable analysis
Variables	HR (95% CI)	P value	HR (95% CI)	P value
Treatment regimen
mFOLFIRINOX vs Gemox	0.559 (0.307–1.020)	0.040	0.353 (0.180–0.694)	0.003
Age
>58 vs ≤58	1.060 (0.579–1.939)	0.851
Sex
male vs female	0.844 (0.626–1.139)	0.268
ECOG
1 vs 0	1.220 (0.664–2.242)	0.523
Primary tumor sites
Intrahepatic	Ref		Ref
Hilar	1.599 (0.869–2.944)	0.131	2.149 (1.113–4.151)	0.023
Distal	0.512 (0.120–2.191)	0.367	0.493 (0.111–2.185)	0.352
Disease status
Metastasis vs Locally advanced	1.111 (0.790–1.564)	0.545
Liver metastasis	1.658 (0.891–3.088)	0.111	3.096 (1.535–6.246)	0.002
CA19–9
>40 vs ≤40	1.867 (0.863–4.036)	0.113	3.622 (1.540–8.523)	0.003

Bold values are statistically significant (p ≤ 0.05)
Ref reference, HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group

ISSN: 1471-2407